glp-1/glp-2 dual agonist Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight

Structural analysis of the dual agonism at GLP-1R and GCGR

26.33

★★★★☆4.8 (126)

🔴Comparison of GLP-1R Mono-Agonist vs. Dual GIPR/GLP-1R Agonist Therapy⤵️ #2025Review 1️⃣ GLP-1 RA are well-studied, but the mechanisms of GIP receptor (GIPR) agonists remain less understood. 2️⃣ GLP-1R monotherapy (e.g., semaglutide) is

23.20

★★★★★4.9 (98)

Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review

23.56

★★★★★5.0 (157)

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

22.19

★★★★★4.7 (84)

Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist

29.22

★★★★★4.9 (203)

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency

25.41

★★★★★5.0 (176)

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

25.00

★★★★★4.8 (132)